Reply to Boyd Et Al., "Evidence That Remdesivir Treatment Reduces Viral Titers in Patients with COVID-19"
Overview
Overview
Journal
Antimicrob Agents Chemother
Publisher
American Society for Microbiology
Specialty
Pharmacology
Date
2024 Nov 7
PMID
39508590
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y
. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578.
PMC: 7190303.
DOI: 10.1016/S0140-6736(20)31022-9.
View
2.
Killingley B, Mann A, Kalinova M, Boyers A, Goonawardane N, Zhou J
. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022; 28(5):1031-1041.
DOI: 10.1038/s41591-022-01780-9.
View
3.
Faghihi I, Yan V
. Remdesivir treatment does not reduce viral titers in patients with COVID-19. Antimicrob Agents Chemother. 2024; 68(8):e0085624.
PMC: 11304678.
DOI: 10.1128/aac.00856-24.
View
4.
Jittamala P, Schilling W, Watson J, Luvira V, Siripoon T, Ngamprasertchai T
. Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV). J Infect Dis. 2023; 228(10):1318-1325.
PMC: 10640773.
DOI: 10.1093/infdis/jiad275.
View
5.
Boyd S, Singh S, Schilling W, White N
. Evidence that remdesivir treatment reduces viral titers in patients with COVID-19. Antimicrob Agents Chemother. 2024; 68(12):e0126624.
PMC: 11619477.
DOI: 10.1128/aac.01266-24.
View